(Q49061414)

English

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

ductal carcinoma

1 reference

based on heuristic

inferred from title

Mieke Van Bockstal

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Olivier De Wever

8

object named as

Olivier De Wever

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Rudy Van den Broecke

6

object named as

Rudy Van den Broecke

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

object named as

Geert Braems

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kathleen Lambein

2

object named as

Kathleen Lambein

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Louis Libbrecht

9

object named as

Louis Libbrecht

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Hannelore Denys

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Ann Nuyts

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Veronique Cocquyt

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

29 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Virchows Archiv

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

465

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

275-289

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24973889%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Is DCIS breast cancer, and how do I treat it?

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Gene amplification in ductal carcinoma in situ of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Significance of HER2 protein examination in ductal carcinoma in situ.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

The receptor expression pattern in ductal carcinoma in situ predicts recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1609-3

21 January 2018

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological Markers Predictive of Invasive Recurrence in DCIS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic classification of breast ductal carcinoma-in-situ

1 reference

https://pubmed.ncbi.nlm.nih.gov/24973889

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49061414&oldid=2246193116"